Published in Nat Med on July 01, 2004
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol (2007) 1.29
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology (2007) 1.09
Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut (2006) 0.89
CEACAM1 and the regulation of mucosal inflammation. Mucosal Immunol (2008) 0.84
Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol (2006) 0.83
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clin Neurosci Res (2005) 0.80
Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses. Methods Enzymol (2010) 0.76
Dendritic Cell Regulation by Cannabinoid-Based Drugs. Pharmaceuticals (Basel) (2010) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology (2004) 14.78
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 8.99
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov (2003) 2.18
Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol (2003) 1.80
Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol (2003) 1.75
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia (2003) 1.44
Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res (2004) 1.25
Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol (2003) 1.17
Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol (2003) 1.15
Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut (1999) 1.10
Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol (2004) 0.99
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest (2008) 3.13
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med (2008) 2.91
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc (2007) 2.84
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Simple quantitative detection of mitochondrial superoxide production in live cells. Biochem Biophys Res Commun (2007) 2.51
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A (2006) 2.08
Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology (2012) 2.01
Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 2.00
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol (2005) 1.98
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology (2008) 1.90
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther (2006) 1.82
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood (2007) 1.76
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem (2003) 1.70
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol (2007) 1.68
Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock (2003) 1.64
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology (2007) 1.59
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol (2007) 1.54
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation (2002) 1.52
Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol (2004) 1.51
Investigational A₃ adenosine receptor targeting agents. Expert Opin Investig Drugs (2011) 1.49
The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One (2008) 1.49
A(2B) adenosine receptors in immunity and inflammation. Trends Immunol (2009) 1.48
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol (2003) 1.48
Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology (2015) 1.48
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med (2003) 1.46
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock (2002) 1.44
Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol (2006) 1.43
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol (2007) 1.39
Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J (2011) 1.38
Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med (2009) 1.38
Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med (2011) 1.36
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2007) 1.34
A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol (2010) 1.33
Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med (2002) 1.31
Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proc Natl Acad Sci U S A (2013) 1.30
Adenosine receptor activation ameliorates type 1 diabetes. FASEB J (2007) 1.27
Endocannabinoids in liver disease. Hepatology (2011) 1.27
Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology (2005) 1.26
The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J (2007) 1.26
Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci (2005) 1.25
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther (2008) 1.24
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem (2003) 1.24
Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat (2009) 1.23
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res (2002) 1.23
Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology (2005) 1.23
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol (2007) 1.22
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res (2009) 1.22
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol (2010) 1.18
Low doses of alcohol substantially decrease glucose metabolism in the human brain. Neuroimage (2005) 1.18
Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep (2004) 1.18
Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation. FASEB J (2004) 1.17
Ecto-5'-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J Immunol (2011) 1.16
Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology (2006) 1.16
Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J (2008) 1.16
Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem (2010) 1.14
Comparison of inflammation, organ damage, and oxidant stress induced by Salmonella enterica serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide. Infect Immun (2002) 1.13
Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock (2004) 1.13
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med (2004) 1.13
Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol (2004) 1.12
AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J (2008) 1.11